Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 18375893

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2008 Apr 1
First author
Seidman AD

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2008 Apr 1;26(10):1585-7. doi: 10.1200/JCO.2007.15.7651.
    note
    Source null
    related pmid
    18375889
    relationship
    Comment in

Authors and identifiers

  1. name
    Seidman AD
    type
    Author
  2. name
    Berry D
    type
    Author
  3. name
    Cirrincione C
    type
    Author
  4. name
    Harris L
    type
    Author
  5. name
    Muss H
    type
    Author
  6. name
    Marcom PK
    type
    Author
  7. name
    Gipson G
    type
    Author
  8. name
    Burstein H
    type
    Author
  9. name
    Lake D
    type
    Author
  10. name
    Shapiro CL
    type
    Author
  11. name
    Ungaro P
    type
    Author
  12. name
    Norton L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Seidman AD
    type
    Author
  2. name
    Berry D
    type
    Author
  3. name
    Cirrincione C
    type
    Author
  4. name
    Harris L
    type
    Author
  5. name
    Muss H
    type
    Author
  6. name
    Marcom PK
    type
    Author
  7. name
    Gipson G
    type
    Author
  8. name
    Burstein H
    type
    Author
  9. name
    Lake D
    type
    Author
  10. name
    Shapiro CL
    type
    Author
  11. name
    Ungaro P
    type
    Author
  12. name
    Norton L
    type
    Author
bibliography ids
  1. nci-bib-cc332c18acaa31b0b9f1f52a
book metadata
content sha256
1ef7b62eadaa7cea3e41d8d32f14ee50703db61ea0f15c398e63841a69e4e1d4
document type
citation
dois
  1. 10.1200/JCO.2007.11.6699
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:18375893
immutable id
pubmed:18375893@1ef7b62eadaa7cea3e41d8d32f14ee50703db61ea0f15c398e63841a69e4e1d4
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
10
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1642-9
volume
26
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2008 Apr 1;26(10):1585-7. doi: 10.1200/JCO.2007.15.7651.
    note
    Source null
    related pmid
    18375889
    relationship
    Comment in
outcomes validated
false
pmid
18375893
provenance
batch id
e663b4be92ee60a9b059
provider
NCBI PubMed ESummary
record sha256
602915f99faf189623e21d6de8d01f72a6f03c789691aed95154a6b937248bba
response sha256
514286e846d1566a3f75c88a4af66b82adfc16ee2368b19bce657f2237aba90d
retrieved at
2026-09-09T23:46:19.265979+00:00
publication date
display
2008 Apr 1
precision
day
year
2008
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/18375893/
title
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Preserved source evidence · Not medical advice